Scleroderma

Results: 143



#Item
1PRESS RELEASE  Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de

PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de

Add to Reading List

Source URL: www.biomedvc.com

Language: English - Date: 2015-11-12 02:47:43
2Technology Opportunity, Ref. No. UZNovel Pharmacological Treatment of Scleroderma This invention relates to a novel pharmacological treatment of scleroderma comprising the administration of miR-29.

Technology Opportunity, Ref. No. UZNovel Pharmacological Treatment of Scleroderma This invention relates to a novel pharmacological treatment of scleroderma comprising the administration of miR-29.

Add to Reading List

Source URL: www.switt.ch

Language: English - Date: 2014-02-01 16:20:50
3Curriculum Vitae BIOGRAPHICAL Name: Janet L. Poole Birthplace: La Jolla, CA Citizenship: USA Business Address:

Curriculum Vitae BIOGRAPHICAL Name: Janet L. Poole Birthplace: La Jolla, CA Citizenship: USA Business Address:

Add to Reading List

Source URL: ot.unm.edu

Language: English - Date: 2015-02-12 12:50:15
4Privacy Policy* April, 2015 The Scleroderma Society of Canada is committed to protecting the privacy of the personal information of its employees, volunteers, members, customers, donors and other stakeholders. We value t

Privacy Policy* April, 2015 The Scleroderma Society of Canada is committed to protecting the privacy of the personal information of its employees, volunteers, members, customers, donors and other stakeholders. We value t

Add to Reading List

Source URL: www.scleroderma.ca

Language: English - Date: 2015-04-09 17:32:17
5Soluble CD90 as biomarker of pulmonary complications in Systemic Sclerosis A new serological two-staged biomarker of pulmonaryarterial hypertension and pulmonary fibrosis Subtitle  Technology

Soluble CD90 as biomarker of pulmonary complications in Systemic Sclerosis A new serological two-staged biomarker of pulmonaryarterial hypertension and pulmonary fibrosis Subtitle Technology

Add to Reading List

Source URL: www.campus-technologies.de

Language: English - Date: 2015-02-19 09:34:47
6Microsoft Word - Ad for Recruitment for Survey26_FINAL.docx

Microsoft Word - Ad for Recruitment for Survey26_FINAL.docx

Add to Reading List

Source URL: www.scleroderma.ca

Language: English - Date: 2015-05-04 18:53:56
7MEMBERS NEWSLETTER ISSUE 33 | JUNE 2010 JUNE FOCUS: THE COST OF ARTHRITIS  How much does arthritis cost you?

MEMBERS NEWSLETTER ISSUE 33 | JUNE 2010 JUNE FOCUS: THE COST OF ARTHRITIS How much does arthritis cost you?

Add to Reading List

Source URL: www.arthritis.org.nz

Language: English - Date: 2011-10-09 22:48:51
8Science / Methodology / Evaluation / Mucinoses / Scleroderma / Questionnaire

DOC Document

Add to Reading List

Source URL: arthritis-research.com

Language: English
9ARTHRITIS  INFORMATION SHEET Scleroderma This sheet has been written for people affected by scleroderma. It provides general

ARTHRITIS INFORMATION SHEET Scleroderma This sheet has been written for people affected by scleroderma. It provides general

Add to Reading List

Source URL: www.arthritiswa.org.au

Language: English - Date: 2012-04-09 23:00:14
10Available online http://arthritis-research.com/content/9/S2/S6  Review Therapeutic targets in systemic sclerosis Christopher P Denton

Available online http://arthritis-research.com/content/9/S2/S6 Review Therapeutic targets in systemic sclerosis Christopher P Denton

Add to Reading List

Source URL: arthritis-research.com

Language: English